Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents

Annals of the Rheumatic Diseases

Volumn 73, Issue 4, 2014, Pages 704-709

  Twig, Gilad ^a,b   Livneh, Avi ^a,c,d   Vivante, Asaf ^a,b,d   Afek, Arnon ^a,d   Shamiss, Ari ^a,d   Derazne, Estela ^b,d   Tzur, Dorit ^b   Ben Zvi, Ilan ^a,c,d   Tirosh, Amir ^a,e   Barchana, Micha ^f   Shohat, Tamy ^f   Golan, Eliezer ^d,g   Amital, Howard ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b MEDICAL CORPS   (Israel)

^c HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MINISTRY OF HEALTH   (Israel)

^g MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BIRTH; BODY MASS; CANCER INCIDENCE; CANCER REGISTRY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; EDUCATIONAL STATUS; END STAGE RENAL DISEASE; ETHNICITY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FOLLOW UP; HUMAN; ISRAEL; KIDNEY AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MILITARY SERVICE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOCIAL STATUS; TREATMENT RESPONSE;

AMYLOIDOSIS; EPIDEMIOLOGY; FAMILIAL MEDITERRANEAN FEVER;

ADOLESCENT; AMYLOIDOSIS; COHORT STUDIES; COMORBIDITY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INCIDENCE; ISRAEL; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASMS; RISK FACTORS; SOCIAL CLASS; YOUNG ADULT;

EID: 84895425848     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202932     Document Type: Article

References (24)

1. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011;7:105-12.
2. Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med Sci 1968;4:995-9.
3. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227-53.
4. Akar S, Yuksel F, Tunca M, et al. Familial Mediterranean Fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine (Baltimore) 2012;91:131-6.
5. Tidow N, Chen X, Muller C, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000;95:1451-5. (Pubitemid 30099860)
6. Celik S, Erikci AA, Tunca Y, et al. The rate of MEFV gene mutations in hematolymphoid neoplasms. Int J Immunogenet 2010;37:387-91.
7. Leiba A, Kark JD, Afek A, et al. Overweight in adolescence is related to increased risk of future urothelial cancer. J Urol 2013;189:25-9.
8. Levi Z, Kark JD, Afek A, et al. Measured body mass index in adolescence and the incidence of pancreatic cancer in a cohort of 720 000 Jewish men. Cancer Causes Control 2012;23:371-8.
9. Levi Z, Kark JD, Barchana M, et al. Measured body mass index in adolescence and the incidence of colorectal cancer in a cohort of 1.1 million males. Cancer Epidemiol Biomarkers Prev 2011;20:2524-31.
10. Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA 2011;306:729-36.
11. Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 2012 Oct. 29:1-7. doi:10.1001/2013.jamainternmed.85. [Epub ahead of print]
12. Gross R, Brammli-Greenberg S, Gordon B, et al. Population-based trends in male adolescent obesity in Israel 1967-2003. J Adolesc Health 2009;44:195-8.
13. Gershoni-Baruch R, Brik R, Lidar M, et al. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 2003;30:308-12. (Pubitemid 36152595)
14. Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000;67:1136-43.
15. Zandman-Goddard G, Amital H, Shamrayevsky N, et al. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) Published Online First: 7 Feb. 2013. doi:10.1093/ rheumatology/kes431.
16. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-12. (Pubitemid 46764102)
17. Soylemezoglu O, Arga M, Fidan K, et al. Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 2010;37:182-9.
18. Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12:72-6.
19. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004;33:273-82. (Pubitemid 38280826)
20. Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5. (Pubitemid 16138694)
21. Ben-Zvi I, Danilesko I, Yahalom G, et al. Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. Isr Med Assoc J 2012;14:221-4.
22. Celik S, Oktenli C, Kilicaslan E, et al. Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia. Int J Hematol 2012;95:285-90.
23. Livneh A, Langevitz P, Pras M. Pulmonary associations in familial Mediterranean fever. Curr Opin Pulm Med 1999;5:326-31.
24. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85. (Pubitemid 27452541)